A Non-Comparative Open Pilot Trial to Assess the Safety and Pharmacokinetics of up to Three Single Doses of AERUMAB 11 (KBPA-101) in Patients With Hospital Acquired Pneumonia Caused by Serotype O11 P. Aeruginosa.

Trial Profile

A Non-Comparative Open Pilot Trial to Assess the Safety and Pharmacokinetics of up to Three Single Doses of AERUMAB 11 (KBPA-101) in Patients With Hospital Acquired Pneumonia Caused by Serotype O11 P. Aeruginosa.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 May 2014

At a glance

  • Drugs Panobacumab (Primary)
  • Indications Nosocomial pneumonia; Pseudomonal infections
  • Focus Adverse reactions; Pharmacokinetics; Registrational
  • Sponsors Kenta Biotech
  • Most Recent Events

    • 03 Jul 2012 Planned number of patients changed from 15 to 40 as reported by EudraCT.
    • 15 Apr 2010 Results were presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases (Abstract No. 1126), according to a Kenta Biotech media release.
    • 14 Sep 2009 Phase IIa data has been presented in a poster session at the 49th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), according to a Kenta Biotech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top